Generation of Human Chiral Metabolites of Simvastatin and Lovastatin by Bacterial CYP102A1 Mutants

Recently, the wild-type and mutant forms of cytochrome P450 BM3 (CYP102A1) from Bacillus megaterium were found to oxidize various xenobiotic substrates, including pharmaceuticals, of human P450 enzymes. Simvastatin and lovastatin, which are used to treat hyperlipidemia and hypercholesterolemia, are oxidized by human CYP3A4/5 to produce several metabolites, including 6′β-hydroxy (OH), 3″-OH, and exomethylene products. In this report, we show that the oxidation of simvastatin and lovastatin was catalyzed by wild-type CYP102A1 and a set of its mutants, which were generated by site-directed and random mutagenesis. One major hydroxylated product (6′β-OH) and one minor product (6′-exomethylene), but not other products, were produced by CYP102A1 mutants. Formation of the metabolites was confirmed by high-performance liquid chromatography, liquid chromatography-mass spectroscopy, and NMR. Chemical methods to synthesize the metabolites of simvastatin and lovastatin have not been reported. These results demonstrate that CYP102A1 mutants can be used to produce human metabolites, especially chiral metabolites, of simvastatin and lovastatin. Our computational findings suggest that a conformational change in the cavity of the mutant active sites is related to the activity change. The modeling results also suggest that the activity change results from the movement of several specific residues in the active sites of the mutants. Furthermore, our computational findings suggest a correlation between the stabilization of the binding site and the catalytic efficiency of CYP102A1 mutants toward simvastatin and lovastatin.

[1]  Heung-Chae Jung,et al.  Oxidation of human cytochrome P450 1A2 substrates by Bacillus megaterium cytochrome P450 BM3 , 2010 .

[2]  Heung-Chae Jung,et al.  Engineering Bacterial Cytochrome P450 (P450) BM3 into a Prototype with Human P450 Enzyme Activity Using Indigo Formation , 2010, Drug Metabolism and Disposition.

[3]  F. Arnold,et al.  A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. , 2009, Chemistry.

[4]  Heung-Chae Jung,et al.  Generation of the Human Metabolite Piceatannol from the Anticancer-Preventive Agent Resveratrol by Bacterial Cytochrome P450 BM3 , 2009, Drug Metabolism And Disposition.

[5]  F. Guengerich.  Introduction: Human metabolites in safety testing (MIST) issue. , 2009, Chemical research in toxicology.

[6]  Kwang-Hyeon Liu,et al.  Generation of Human Metabolites of 7-Ethoxycoumarin by Bacterial Cytochrome P450 BM3 , 2008, Drug Metabolism and Disposition.

[7]  N. Vermeulen,et al.  Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3 , 2008, Proteins.

[8]  Andreas Schmid,et al.  Heme-iron oxygenases: powerful industrial biocatalysts? , 2008, Current opinion in chemical biology.

[9]  F. Guengerich,et al.  Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. , 2008, Protein expression and purification.

[10]  N. Vermeulen,et al.  Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. , 2008, Chemico-biological interactions.

[11]  Jean‐Didier Maréchal,et al.  Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency. , 2007, Journal of molecular biology.

[12]  Heung-Chae Jung,et al.  The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. , 2007, Trends in biotechnology.

[13]  Bernard Testa,et al.  Predicting the Oxidative Metabolism of Statins: An Application of the MetaSite® Algorithm , 2007, Pharmaceutical Research.

[14]  N. Vermeulen,et al.  Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. , 2007, Journal of medicinal chemistry.

[15]  Vlada B Urlacher,et al.  Cytochrome P450 monooxygenases: perspectives for synthetic application. , 2006, Trends in biotechnology.

[16]  T. Ahn,et al.  Functional expression of human cytochrome P450 enzymes in Escherichia coli. , 2006, Current drug metabolism.

[17]  P. Neuvonen,et al.  Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. , 2005, Basic & clinical pharmacology & toxicology.

[18]  Imad Hanna,et al.  Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli , 2005, Journal of Industrial Microbiology and Biotechnology.

[19]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[20]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[21]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[22]  A. Sánchez Navarro,et al.  Clinical pharmacokinetics of statins. , 2003, Methods and findings in experimental and clinical pharmacology.

[23]  F Peter Guengerich,et al.  Cytochromes P450, drugs, and diseases. , 2003, Molecular interventions.

[24]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[25]  F. Guengerich,et al.  Cytochrome p450 enzymes in the generation of commercial products , 2002, Nature Reviews Drug Discovery.

[26]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[27]  T. Rushmore,et al.  Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. , 2000, Metabolic engineering.

[28]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[29]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[30]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[31]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[32]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[33]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[34]  B. Buckland,et al.  Development of a large‐scale continuous substrate feed process for the biotransformation of simvastatin by Nocardia s.p. , 1991, Biotechnology and bioengineering.

[35]  B. Arison,et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[36]  I. Chen,et al.  Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[37]  W. F. Hoffman,et al.  Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[38]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[39]  H. Berendsen,et al.  ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS , 1977 .

[40]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.